

Monoclonal Antibody Drugs

Per Systemic Therapy Policy III- 10

Dose variance of +/-10% is permitted for monoclonal antibody drugs when dosing is based on body weight or body surface area:

Monoclonal Antibody Drugs
alemtuzumab
atezolizumab
avelumab
bevacizumab
blinatumomab
cemiplimab
cetuximab
daratumumab
denosumab (XGEVA, WYOST)
dinutuximab
dostarlimab
durvalumab
epcoritamab
ipilimumab
isatuximab
mogamulizumab
nivolumab
nivolumab-relatlimab
obinutuzumab
panitumumab
pembrolizumab
pertuzumab
ramucirumab
rituximab
siltuximab
teclistamab
trastuzumab
tremelimumab